NASDAQ:CASI CASI Pharmaceuticals - CASI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.99 -0.08 (-3.86%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.99▼$2.0950-Day Range$1.48▼$2.0852-Week Range$1.45▼$10.30Volume21,875 shsAverage Volume36,856 shsMarket Capitalization$27.08 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability CASI Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside402.5% Upside$10.00 Price TargetShort InterestHealthy2.13% of Float Sold ShortDividend StrengthN/ASustainability-1.50Upright™ Environmental ScoreNews Sentiment0.33Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.16) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.59 out of 5 starsMedical Sector93rd out of 1,028 stocksBiological Products, Except Diagnostic Industry17th out of 168 stocks 3.5 Analyst's Opinion Consensus RatingCASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, CASI Pharmaceuticals has a forecasted upside of 402.5% from its current price of $1.99.Amount of Analyst CoverageCASI Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.13% of the float of CASI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCASI Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in CASI Pharmaceuticals has recently decreased by 5.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCASI Pharmaceuticals does not currently pay a dividend.Dividend GrowthCASI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCASI Pharmaceuticals has received a 63.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CASI Pharmaceuticals is -1.50. Previous Next 3.0 News and Social Media Coverage News SentimentCASI Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CASI Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for CASI on MarketBeat in the last 30 days. MarketBeat Follows4 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders26.59% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.62% of the stock of CASI Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($2.16) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CASI Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CASI Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCASI Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CASI Pharmaceuticals (NASDAQ:CASI) StockCASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.Read More Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CASI Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comShort Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 5.9%January 31, 2023 | americanbankingnews.comStockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI)February 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 30, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Verastem (VSTM)January 18, 2023 | marketwatch.comMarginal Zone B-cell Lymphoma Drugs Market Size, Outlook, Share, Prominent Players, Growth, and Forecast 2029January 6, 2023 | finance.yahoo.comCASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINAJanuary 6, 2023 | finance.yahoo.comCasi Pharmaceuticals to run clinical trial for multiple myeloma drug in ChinaJanuary 5, 2023 | marketwatch.comAnalysis of Ibritumomab Tiuxetan Market for the Period 2023 to 2028 : Development, Growth and Key FactorsFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 16, 2022 | msn.comChinese pharmas and biotechs risk of delisting averted as US regulators review auditsDecember 15, 2022 | finance.yahoo.comCASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNovember 17, 2022 | finance.yahoo.comCASI Pharmaceuticals Third Quarter 2022 Earnings: Beats ExpectationsNovember 14, 2022 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSNovember 14, 2022 | finance.yahoo.comCASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue EstimatesNovember 9, 2022 | nasdaq.comScynexis (SCYX) Reports Q3 Loss, Misses Revenue EstimatesOctober 7, 2022 | forbes.comCasi PharmaceuticalsSeptember 23, 2022 | marketwatch.comCASI Pharmaceuticals Exits Juventas Biotechnology InvestmentSeptember 23, 2022 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETSeptember 9, 2022 | msn.comCASI Pharmaceuticals Earnings Perspective: Return On Capital EmployedSeptember 7, 2022 | nasdaq.comWednesday 9/7 Insider Buying Report: JELD, CASISeptember 7, 2022 | finance.yahoo.comCASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINAAugust 29, 2022 | msn.comCASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively BuyingAugust 14, 2022 | nasdaq.comStrong week for CASI Pharmaceuticals (NASDAQ:CASI) shareholders doesn't alleviate pain of three-year lossAugust 12, 2022 | seekingalpha.comCASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call TranscriptAugust 12, 2022 | finance.yahoo.comEven after rising 58% this past week, CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still down 88% over the past three yearsAugust 12, 2022 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTSAugust 11, 2022 | msn.com7CASI : CASI Pharmaceuticals Earnings: A PreviewSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CASI Company Calendar Last Earnings11/14/2022Today2/05/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CASI CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone(240) 864-2600Fax301-315-2437Employees176Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+402.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,650,000.00 Net Margins-73.17% Pretax Margin-71.10% Return on Equity-37.59% Return on Assets-21.05% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.68 Sales & Book Value Annual Sales$30.17 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value$6.04 per share Price / Book0.33Miscellaneous Outstanding Shares13,610,000Free Float9,988,000Market Cap$27.08 million OptionableNot Optionable Beta0.36 Key ExecutivesWei-Wu HeExecutive Chairman & Chief Executive OfficerWei ZhangPresidentCynthia Wong HuCOO, Secretary & General CounselWei Hao XuChief Financial OfficerAlexander A. ZukiwskiChief Medical OfficerKey CompetitorsEntera BioNASDAQ:ENTXIdera PharmaceuticalsNASDAQ:IDRAPeak BioNASDAQ:PKBOCodiak BioSciencesNASDAQ:CDAKAIM ImmunoTechNYSE:AIMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 48,689 shares on 11/15/2022Ownership: 1.892%Renaissance Technologies LLCBought 10,400 shares on 11/14/2022Ownership: 0.076%James HuangBought 33,300 shares on 9/8/2022Total: $142,524.00 ($4.28/share)James HuangBought 19,162 shares on 9/6/2022Total: $74,540.18 ($3.89/share)James HuangBought 39,527 shares on 8/26/2022Total: $148,226.25 ($3.75/share)View All Insider TransactionsView All Institutional Transactions CASI Stock - Frequently Asked Questions Should I buy or sell CASI Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares. View CASI analyst ratings or view top-rated stocks. What is CASI Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 12-month target prices for CASI Pharmaceuticals' shares. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 402.5% from the stock's current price. View analysts price targets for CASI or view top-rated stocks among Wall Street analysts. How have CASI shares performed in 2023? CASI Pharmaceuticals' stock was trading at $1.79 on January 1st, 2023. Since then, CASI shares have increased by 11.2% and is now trading at $1.99. View the best growth stocks for 2023 here. Are investors shorting CASI Pharmaceuticals? CASI Pharmaceuticals saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 277,800 shares, a decrease of 5.9% from the December 31st total of 295,200 shares. Based on an average daily volume of 33,900 shares, the short-interest ratio is currently 8.2 days. Approximately 2.1% of the company's shares are sold short. View CASI Pharmaceuticals' Short Interest. When is CASI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our CASI earnings forecast. How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Monday, November, 14th. The biotechnology company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.13. The biotechnology company had revenue of $10.21 million for the quarter, compared to analyst estimates of $10.40 million. CASI Pharmaceuticals had a negative net margin of 73.17% and a negative trailing twelve-month return on equity of 37.59%. When did CASI Pharmaceuticals' stock split? Shares of CASI Pharmaceuticals reverse split on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM). What is CASI Pharmaceuticals' stock symbol? CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI." Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James Huang, Larry Zhang, Weihao Xu and Wei-Wu He. View institutional ownership trends. How do I buy shares of CASI Pharmaceuticals? Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CASI Pharmaceuticals' stock price today? One share of CASI stock can currently be purchased for approximately $1.99. How much money does CASI Pharmaceuticals make? CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $27.08 million and generates $30.17 million in revenue each year. The biotechnology company earns $-36,650,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. How many employees does CASI Pharmaceuticals have? The company employs 176 workers across the globe. How can I contact CASI Pharmaceuticals? CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at (240) 864-2600, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437. This page (NASDAQ:CASI) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.